Following a full submission considered under the orphan equivalent process:
pertuzumab (Perjeta®) is not recommended for use within NHSScotland.
Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature.
The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- pertuzumab (Perjeta)
- SMC ID:
In combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC) at high risk of recurrence.
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Not recommended
- Date advice published:
- 07 October 2019